Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95. (Q42926170)
Jump to navigation
Jump to search
scientific article published on 25 August 2010
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95. |
scientific article published on 25 August 2010 |
Statements
Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95 (English)
Philippe Colombat
Bernard Desablens
Jean Pierre Vilque
Virginie Lucas
Antoine Thyss
Audrey Simon
Michel Peoch
Philippe Casassus
Eric Deconinck
Olivier Tournilhac
Houchingue Eghbali
Charles Foussard
Jerome Jaubert
Jean François Rossi
Frederic Maloisel
Thierry Lamy
25 August 2010
1 reference